Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review

Summary Epidermal growth factor receptor (EGFR) inhibitors, such as the monoclonal antibodies cetuximab and panitumumab, have proven efficacy in various types of cancer. However, these agents frequently result in skin toxicity, due to the expression of the EGFR in the skin. A correlation between the...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer treatment reviews Vol. 38; no. 5; pp. 505 - 514
Main Authors:	Baas, J.M, Krens, L.L, Guchelaar, H.-J, Ouwerkerk, J, Jong, F.A de, Lavrijsen, A.P.M, Gelderblom, H
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 01-08-2012
Subjects:	Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cetuximab EGFR inhibitors Guideline Hematology, Oncology and Palliative Medicine Humans Neoplasms - drug therapy Prophylaxis Randomized Controlled Trials as Topic Receptor, Epidermal Growth Factor - antagonists & inhibitors Skin - drug effects Skin Diseases - chemically induced Skin Diseases - physiopathology Skin toxicity Treatment Outcome Guideline EGFR inhibitors Skin toxicity Prophylaxis
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Summary Epidermal growth factor receptor (EGFR) inhibitors, such as the monoclonal antibodies cetuximab and panitumumab, have proven efficacy in various types of cancer. However, these agents frequently result in skin toxicity, due to the expression of the EGFR in the skin. A correlation between the occurrence of skin toxicity and anti-tumor activity has been suggested in several phase III studies. However, since skin toxicity may impair the quality of life, and severe skin toxicity requires dose reduction or interruption, adequate and timely management of skin toxicity is important to maximize the anti-tumor efficacy of the EGFR inhibitor, as well as maintaining the patient’s quality of life. Due to the small number of randomized controlled trials conducted in the field of EGFR inhibitor-induced skin toxicity so far, it is not possible yet to generate evidence based guidelines on its management. Here, we review and discuss available trials and case studies reporting on the management of EGFR inhibitor-induced skin toxicity.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	0305-7372 1532-1967
DOI:	10.1016/j.ctrv.2011.09.004